Category Human Rights

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture.

Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first was with Dr Othoman Mellouk.]

Прекратить неавторизованный доступ к генетическим ресурсам (а именно, Биопиратство): принцип ограниченной открытости

«Доступ к генетическим ресурсам» и «справедливое и честное распределение выгод от их использования» были камнем предкновения на всех тринадцати Конференциях сторон-участников Соглашения Организации Объединенных Наций от 1993 года о Биологическом разнoобразии (CBD). Слова в кавычках составляют третью задачу договора, которая переплетена с двумя первыми, а именно с задачей консервации и устойчивого использования. По первым буквам английского названия эта задача сокращенно обозначается как «ABS». Несмотря на 25 лет усилий и при размерах био-экономики порядка 1 триллиона долларов [1], было заключено немного контрактов [2]. И в этом малом количестве контрактов денежная часть так незначительна, что их участники не пожелали ее обнародовать. «Закон ABS Бразилии» от 2015, который вошел в силу 6 ноября 2017, позволяет чтобы отчисления от суммы продаж составляли всего одну десятую процента[3]. Используя выражение известного ученого-законоведа, потребитель платит «пшик» авторам биоресурсов.

The Myth Behind Health And Trade Agreements – Q&A With Othoman Mellouk

Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is one of two. An interview with Carlos Correa will follow.]

Indigenous Peoples Seek Involvement In WTO To Defend Rights (Video)

Indigenous peoples are losing their genetic resources and traditional knowledge and need to be involved in negotiations on World Trade Organization intellectual property rules and the UN Convention on Biological Diversity, representatives told a conference on the subject last week. In a podcast and video interview with Intellectual Property Watch below, the indigenous representatives explain their case.

En finir avec l’accès aux ressources génétiques sans autorisation (c’est-à-dire avec la biopiraterie): « l’ouverture limitée »

L' « accès aux ressources génétiques » et le « partage juste et équitable des avantages découlant de leur utilisation » s’est révelé un véritable casse-tête pour l’ensemble des 13 Conférences des Parties à la Convention des Nations Unies sur la Diversité Biologique (CDB). La formule, entre guillemets, qu’on désigne par l’acronyme « APA », se réfère au troisième objectif de la Convention, lequel est étroitement liée aux deux premiers, à savoir la conservation et l’utilisation durable de ces ressources. Malgré 25 années consécutives d’efforts et dans un contexte où le marché de la biotechnologie représente, annuellement, un trillion de dollars, peu d’accords APA ont été conclus jusqu’ici. Les bénéfices monétaires des quelques contrats existants sont si faibles que les contractants répugnent à les dévoiler. La « législation APA brésilienne » de 2015, qui est entrée en vigueur le 6 novembre 2017, permet par exemple d’offrir des royalties jusqu’à un dixième de pour cent du chiffre d’affaire. Selon les termes d’un éminent juriste: « les usagers paient des cacachuètes pour se servir de la biodiversité ».

Experts To Regulators: AI Is A Panacea – With Hidden Dangers To Humanity

The heads of national telecommunications and technology regulatory authorities are gathering next month at the International Telecommunication Union to address new technologies. Not surprisingly, artificial intelligence and data hold centre stage in the programme. The meeting comes after a recent event at the United Nations where divergent voices recognised the potential beneficial uses of new technology, but warned against the undeclared intentions behind it. Separately, a new study from the Massachusetts Institute of Technology shows the influence of data in machine learning algorithms with chilling consequences.

Pondo termo ao acesso não autorizado aos recursos genéticos (quer dizer, biopirataria): acesso aberto limitado

O “acesso aos recursos genéticos” e a “participação justa e equitativa dos benefícios provenientes de sua utilização” vêm aturdindo delegados e delegações das 13 Conferências das Partes da Convenção das Nações Unidas sobre Diversidade Biológica, que entrou em vigor no ano de 1993. A expressão entre aspas conhecida pela sigla em inglês “ABS” é o terceiro objetivo do Convênio e se encontra entrelaçada pelos dois primeiros objetivos que são a conservação e o uso sustentável. Apesar de 25 anos de esforços e de uma bioeconomia de quase um trilhão de dólares, são muito poucos os contratos celebrados. Desses poucos, os benefícios monetários são tão baixos que as partes contratantes relutam em revelá-los. A “Lei brasileira de ABS” de 2015, que entrou em vigor no dia 6 de novembro de 2017 permite, por exemplo, a obtenção de royalties sobre vendas líquidas tão baixos que isso implica a celebração de contratos pela bagatela de uma décima parte de um por cento. Citando as palavras de um jurista erudito, os Usuários pagam “uma miséria pela biodiversidade”.

Legislation For South Africa’s New IP Policy Likely After Elections Next Year

Legislative changes giving effect to South Africa’s recently published Intellectual Property Policy “Phase 1” will not take place during this term of government, the country’s trade minister has said. Meanwhile, a side-by-side comparison with the 2017 draft legislation shows a series of changes in the final policy, and the pharmaceutical industry is complaining but appears determined to continue investing in the country.

Opportunities, Risks Of Rapid Technological Change Discussed At UN

The Third annual United Nations Multi-stakeholder Forum on Science, Technology and Innovation for the Sustainable Development Goals opened with Marie Chatardová, president of the Economic and Social Council, stating that “STI is shaping the trajectory of our society, helping the world address global challenges and achieve Sustainable Development Goals.”